«12345»Seite
5 articles with references, page 2 of 5

Review article

Inpatient Treatment of Type 2 Diabetes

Dtsch Arztebl Int 2012; 109(26): 466-74; DOI: 10.3238/arztebl.2012.0466

Breuer, T G K; Meier, J J

1. Heidemann C, Du Y, Scheidt-Nave C: Diabetes mellitus in Deutschland. Robert-Koch-Institut (ed.). Berlin 2011.
2. Siegel E: Medical care management of patients with diabetes mellitus in hospitals. The Ludwigshafen-Limburger diabetes model. Der Diabetologe 2008; 4: 20–9. CrossRef
3. American-Diabetes-Association: Standards of medical care in diabetes 2011. Diabetes Care 2011; 34 (Suppl 1): 11–61. CrossRef MEDLINE
4. Matthaei S, Bierwirth R, Fritsche A, et al.: Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie. Diabetologie und Stoffwechsel 2009; 4: 32–64. CrossRef
5. Statistisches-Bundesamt: Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik). Diagnosen, Prozeduren, Fallpauschalen und Case Mix der vollstationären Patientinnen und Patienten in Krankenhäusern 2010.
6. Kunz R, Burnand B, Schunemann HJ: The GRADE System. An international approach to standardize the graduation of evidence and recommendations in guidelines. Internist 2008; 49: 673–80. CrossRef MEDLINE
7. Rote-Liste-Service-GmbH: Fachinformationsverzeichnis Deutschland. www.fachinfo.de.
8. Clement S, Braithwaite SS, Magee MF, et al.: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004; 27: 553–91. CrossRef MEDLINE
9. Siegmund T: Insulintherapie unter besonderen Bedingungen. In: T Siegmund (ed.): Therapieregister Diabetes für die Klinik. Berlin, Köln: Lehmanns Media GmbH 2011; 74–97.
10. Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765–72. CrossRef MEDLINE
11. Schernthaner G: Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010; 160: 8–19. CrossRef MEDLINE
12. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854–65. CrossRef MEDLINE
13. Lloyd-Jones DM, Larson MG, Leip EP, et al.: Lifetime risk for
developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068–72. CrossRef MEDLINE
14. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345–51. CrossRef MEDLINE
15. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale Versorgungsleitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter – Langfassung. Version 1.X. 2010. www.diabetes.versorgungsleitlinien.de.
16. Siegel E, Schröder F, Kunder J, Dreyer M: Medikamente. In: Siegel E, Schröder F, Kunder J, Dreyer M (eds.): Diabetes mellitus XXS
pocket. Grünwald: Börm Bruckmeiner Verlag GmbH 2011; 93–116.
17. Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2003; (2): CD002967. MEDLINE
18. Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 1984; 27: 351–7. CrossRef MEDLINE
19. Vogt C, Dreyhaupt J, Hasslacher C: Influence of declining kidney function on Insulin dosage in type 1- and type 2-diabetic patients. Diabetologie und Stoffwechsel 2006; 1: 311–8. CrossRef
20. Umpierrez GE, Smiley D, Zisman A, et al.: Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007; 30: 2181–6. CrossRef MEDLINE
21. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073–84. CrossRef MEDLINE
22. Holman RR, Farmer AJ, Davies MJ, et al.: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736–47. CrossRef MEDLINE
23. Umpierrez GE, Hor T, Smiley D, et al.: Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 564–9. CrossRef MEDLINE
24. Goldberg PA, Siegel MD, Sherwin RS, et al.: Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004; 27: 461–7. CrossRef MEDLINE
25. European Commission: Commission Implementing Decision of 22.11.2011 amending the marketing authorisation granted by Decision C (2007)1362 for „Januvia – Sitagliptin“, a medicinal product for human use. 2011.
e1. Van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359–67. MEDLINE
e2. Finfer S, Chittock DR, Su SY, et al.: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283–97. MEDLINE
e3. Van den Berghe G, Wilmer A, Hermans G, et al.: Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449–61. MEDLINE
e4. Inzucchi SE: Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355: 1903–11. MEDLINE
e5. Trence DL, Kelly JL, Hirsch IB: The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab 2003; 88: 2430–7. CrossRef MEDLINE
e6. Zander JF, Risse A: Perioperative Behandlung und Einstellung des Diabetes mellitus. Orthopäde 2009; 38: 818–827. CrossRef MEDLINE
e7. Mehnert F, Mehnert B, Pereira PL, Clausen CD, Häring HU: Metformin und intravenöse Röntgenkontrastmittel: Ein Risiko? Diabetes und Stoffwechsel 2000; 9: 235–8.
e8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–53. CrossRef MEDLINE
e9. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 (Suppl 2): B21–9. MEDLINE
e10. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72. MEDLINE
e11. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59. MEDLINE
e12. Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39. MEDLINE
e13. Bell DS: Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006; 174: 185–6. CrossRef MEDLINE PubMed Central
e14. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA: Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9–12. MEDLINE PubMed Central
e15. Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S: Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care 2009; 32 (Suppl 2): 223–31. MEDLINE
e16. Williams-Herman D, Engel SS, Round E, et al.: Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2008; 10: 7. MEDLINE
e17. Nikolaidis LA, Mankad S, Sokos GG, et al.: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962–5. MEDLINE
e18. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP: DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010; 3: 195–201. CrossRef MEDLINE
e19. Mamas MA, Neyses L, Fath-Ordoubadi F: A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction. Exp Clin Cardiol 2010; 15: e20–4. MEDLINE PubMed Central
e20. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 29: 166–76. MEDLINE
e21. Futh R, Dinh W, Bansemir L, et al.: Newly detected glucose disturbance is associated with a high prevalence of diastolic dysfunction: double risk for the development of heart failure? Acta Diabetol 2009; 46: 335–8. MEDLINE
e22. Tzoulaki I, Molokhia M, Curcin V, et al.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731. MEDLINE
e23. Bennett WL, Maruthur NM, Singh S, et al.: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602–13. MEDLINE
e24. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): 1–266. CrossRef MEDLINE
e25. Holstein A, Stumvoll M: Contraindications can damage your health–is metformin a case in point? Diabetologia 2005; 48: 2454–9. MEDLINE
e26. Nowicki M, Rychlik I, Haller H, et al.: Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract 2011; 65: 1230–9. MEDLINE
e27. Hasslacher C, Vogt C, Raupp D, Dreyhaupt J: Insulin requirement in patients with type 1 diabetes with reduced renal function: human insulin versus analogue insulin. Dtsch Med Wochenschr 2007; 132: 2500–4. MEDLINE
e28. Kutoh E: Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother 2005; 3: 270–3. CrossRef MEDLINE
e29. Ahmed MH, Byrne CD: Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009; 11: 188–95. CrossRef MEDLINE
e30. Garinis GA, Fruci B, Mazza A, et al.: Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010; 34: 1255–64. MEDLINE
e31. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N: Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893–4. MEDLINE
e32. Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K: Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009; 10: 5–13. CrossRef MEDLINE
e33. Migoya EM, Stevens CH, Bergman AJ, et al.: Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16: e165–70. MEDLINE
e34. Nielsen LL, Okerson T, Holcombe J, Hoogwerf B: Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2: 255–60. MEDLINE PubMed Central